Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma | Zendy

Marleen Kars | Zendy; Victoria Delgado | Zendy; Eduard R. Holman | Zendy; Richard A. Feelders | Zendy; Johannes W. A. Smit | Zendy; Johannes A. Romijn | Zendy; Jeroen J. Bax | Zendy; Alberto M. Pereira | Zendy

Open Access

Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma

Author(s) -

Marleen Kars,

Victoria Delgado,

Eduard R. Holman,

Richard A. Feelders,

Johannes W. A. Smit,

Johannes A. Romijn,

Jeroen J. Bax,

Alberto M. Pereira

Publication year - 2008

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2007-2658

Subject(s) - cabergoline , medicine , pergolide , prolactinoma , valvular heart disease , dopamine agonist , gastroenterology , heart valve , regurgitation (circulation) , cardiology , endocrinology , dopamine , hormone , dopaminergic , prolactin

Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline has been associated with an increased frequency of valvular heart disease in Parkinson's disease. The aim of the present study was to assess the prevalence of valvular heart disease in patients treated with dopamine agonists for prolactinomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research